Revolution Medicines Updates Clinical Trials for RMC-6236 and RMC-6291

Details

reported updated clinical safety, tolerability, and activity data for its RAS(ON) inhibitors, RMC-6236 and RMC-6291, in various cancer types. For RMC-6236, in patients with pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), the drug demonstrated manageable safety profiles with tumor responses observed. In combination with pembrolizumab, RMC-6236 showed tolerability in NSCLC patients. For RMC-6291, in patients with advanced RAS G12C mutant solid tumors, the combination with RMC-6236 was generally well tolerated with initial signs of antitumor activity. These updates support Revolution Medicines' ongoing development plans for these inhibitors.

Items reported

About Revolution Medicines Inc.

Revolution Medicines Inc. is a biotechnology company primarily focused on the development of targeted therapies for cancer treatment. The company aims to create innovative drugs by leveraging the potential of inhibitors that target specific oncogenic pathways. Revolution Medicines Inc. specializes in synthetic lethal technologies and non-covalent inhibitors to address complex molecular targets found in cancer cells. With a strong emphasis on research and development, it collaborates with academic institutions and partners within the biopharmaceutical industry to advance its pipeline of drug candidates. Revolution Medicines Inc. is significantly involved in the oncology sector, with potential impacts on patient care through its commitment to developing precision medicines. As a key player in the biotech landscape, the company contributes to the ongoing evolution of cancer treatment methodologies, seeking to extend and improve patients' lives through state-of-the-art therapeutic options.